Publication | Closed Access

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis

Hematological MalignancyTumor BiologyRnf20/rnf40/wac-h2b Ubiquitination AxisMedicineVivo Anti-leukaemic ActivityMixed-phenotype Acute LeukemiaHematologyImmunologyHdac Inhibitor PanobinostatOncologyCell BiologyCancer ResearchMyeloid Neoplasia